Human IFN-gamma protein (Active Recombinant) (No tag) (STJP001117)
SPECIFICATIONS
HostE.coli
ConjugationUnconjugated
ImmunogenRecombinant Human Interferon Gamma Protein is produced by E. coli expression system. The target protein is expressed with sequence ( Gln24-Gln166) of human Interferon Gamma (Accession #NP_000610.2).
General Information
| Short Description | Active Recombinant-Human IFN-gamma-No tag protein was developed in e.coli using the region Gln24-Gln166. For use in research applications. |
| Host | E.coli |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Conjugation | Unconjugated |
| Formulation | Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
| Storage Instruction | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Immunoreactivity | 1.Measured by its binding ability in a functional ELISA. Immobilized Human FNGR1/CD119 at 1 Mu g/mL (100 Mu L/well) can bind Human IFNG with a linear range of 0.98-1.97 ng/mL.|2.Measured in a cytotoxicity assay using HT-29 cells. The ED50 |
| Determination Method | < 0.1 EU/Mu g of the protein by LAL method. |
Target Information
| Gene Symbol | IFNG |
| Gene ID | 3458 |
| Uniprot ID | IFNG_HUMAN |
| Immunogen | Recombinant Human Interferon Gamma Protein is produced by E. coli expression system. The target protein is expressed with sequence ( Gln24-Gln166) of human Interferon Gamma (Accession #NP_000610.2). |
| Immunogen Region | Gln24-Gln166 |
| Immunogen Sequence | QDPYVKEAENLKKYFNAGHS DVADNGTLFLGILKNWKEES DRKIMQSQIVSFYFKLFKNF KDDQSIQKSVETIKEDMNVK FFNSNKKKRDDFEKLTNYSV TDLNVQRKAIHELIQVMAEL SPAAKTGKRKRSQMLFRGRR ASQ |
Additional Info
| Tissue Specificity | Released primarily from activated T lymphocytes. |
| Post Translational Modifications | Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161. |
| Function | Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription. Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits. In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading. Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference. Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL. Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation. |
| Protein Name | Interferon GammaIfn-GammaImmune Interferon |
| Database Links | Reactome: R-HSA-877300Reactome: R-HSA-877312Reactome: R-HSA-8877330Reactome: R-HSA-8950505Reactome: R-HSA-9732724 |
| Cellular Localisation | Secreted |
| Alternative Protein Names | Interferon Gamma proteinIfn-Gamma proteinImmune Interferon proteinIFNG protein |
Information sourced from Uniprot.org